|
Market Closed -
NSE India S.E.
15:05:08 19/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 2,608.50 INR | -1.42% |
|
-2.57% | +28.17% |
| 11-09 | Acucort signs exclusive agreement for Zeqmelit in Canada - launch expected in 2028 | FW |
| 11-06 | Glenmark Pharmaceuticals Limited, Q2 2027 Earnings Call, Nov 06, 2026 |
Company Valuation: Glenmark Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 124,718 | 131,124 | 270,463 | 434,866 | 601,567 | 736,171 | - | - |
| Change | - | 5.14% | 106.27% | 60.79% | 38.33% | 22.38% | - | - |
| Enterprise Value (EV) 1 | 150,223 | 162,699 | 263,786 | 442,540 | 595,740 | 723,918 | 714,456 | 705,856 |
| Change | - | 8.3% | 62.13% | 67.76% | 34.62% | 21.52% | -1.31% | -1.2% |
| P/E | 13.2x | 44.1x | -18x | 41.5x | 44.2x | 32.9x | 26.8x | 23.5x |
| PBR | 1.37x | 1.38x | 3.45x | 4.91x | 5.72x | 5.92x | 4.89x | 4.12x |
| PEG | - | -0.6x | 0x | -0x | 1.5x | 0.5x | 1.2x | 1.7x |
| Capitalization / Revenue | 1.01x | 1.01x | 2.29x | 3.26x | 3.54x | 4.35x | 3.91x | 3.48x |
| EV / Revenue | 1.22x | 1.25x | 2.23x | 3.32x | 3.51x | 4.27x | 3.8x | 3.34x |
| EV / EBITDA | 6.47x | 7.14x | 22.1x | 18.8x | 13x | 20x | 16.5x | 14.5x |
| EV / EBIT | 8.19x | 9.76x | 43x | 23.7x | 14.9x | 24.1x | 19.6x | 17.4x |
| EV / FCF | 47.2x | 923x | -22.7x | -28.1x | 28.5x | 33.4x | 41.1x | 32.6x |
| FCF Yield | 2.12% | 0.11% | -4.41% | -3.56% | 3.5% | 2.99% | 2.43% | 3.06% |
| Dividend per Share 2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 4.25 | 4.02 | 3.75 |
| Rate of return | 0.57% | 0.54% | 0.26% | 0.16% | 0.12% | 0.16% | 0.15% | 0.14% |
| EPS 2 | 33.4 | 10.53 | -53.22 | 37.11 | 48.24 | 79.35 | 97.43 | 110.9 |
| Distribution rate | 7.49% | 23.7% | -4.7% | 6.74% | 5.18% | 5.36% | 4.13% | 3.38% |
| Net sales 1 | 123,409 | 129,901 | 118,131 | 133,217 | 169,825 | 169,387 | 188,066 | 211,257 |
| EBITDA 1 | 23,203 | 22,784 | 11,953 | 23,514 | 45,724 | 36,253 | 43,263 | 48,791 |
| EBIT 1 | 18,336 | 16,671 | 6,134 | 18,654 | 39,989 | 29,996 | 36,404 | 40,608 |
| Net income 1 | 9,936 | 2,972 | -15,017 | 10,471 | 13,619 | 21,961 | 27,354 | 30,536 |
| Net Debt 1 | 25,505 | 31,575 | -6,677 | 7,674 | -5,827 | -12,253 | -21,715 | -30,314 |
| Reference price 2 | 442.00 | 464.70 | 958.45 | 1,541.05 | 2,131.70 | 2,608.50 | 2,608.50 | 2,608.50 |
| Nbr of stocks (in thousands) | 282,168 | 282,168 | 282,188 | 282,188 | 282,201 | 282,220 | - | - |
| Announcement Date | 27/05/22 | 19/05/23 | 24/05/24 | 23/05/25 | 29/05/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 34.79x | 4.34x | 20.26x | 0.16% | 7.99B | ||
| 40.47x | 13.71x | 29.06x | 0.49% | 1,232B | ||
| 39.91x | 6.7x | 18.85x | 1.95% | 656B | ||
| 36.46x | 8.39x | 17.35x | 2.41% | 506B | ||
| 21.68x | 5.25x | 13.15x | 2.48% | 382B | ||
| 97.8x | 5.62x | 23.94x | 2.47% | 340B | ||
| 23.54x | 5.68x | 13.81x | 2.8% | 294B | ||
| 23.52x | 4.72x | 13.42x | 1.86% | 278B | ||
| 22.92x | 7.08x | 13.01x | 2.27% | 240B | ||
| -39.74x | 7.35x | 46.29x | 1.95% | 210B | ||
| Average | 30.13x | 6.88x | 20.91x | 1.89% | 415B | |
| Weighted average by Cap. | 35.44x | 8.61x | 21.92x | 1.74% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLENMARK Stock
- Valuation Glenmark Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
















